Biotech Veteran Jean-Paul Kress Takes Helm at Vor Biopharma in Leadership Shake-up

Rhea-AI Filing Summary

Jean-Paul Kress has filed a Form 3 (Initial Statement of Beneficial Ownership) with the SEC upon joining Vor Biopharma (NYSE: VOR) as CEO and Chairman of the Board, effective June 25, 2025.

Key details from the filing:

• Kress currently holds no beneficial ownership of any Vor Biopharma securities, either direct or indirect
• He serves in dual roles as both Director and Executive Officer
• The filing was submitted by attorney-in-fact Sherell Bacchas on June 27, 2025
• Business address is listed as 100 Cambridgepark Drive, Suite 101, Cambridge, MA

This Form 3 filing is a standard regulatory requirement for new officers and directors of public companies, establishing their initial securities ownership baseline for future transaction reporting.

Positive

• None.

Negative

• New CEO and Chairman Jean-Paul Kress reports owning zero shares or derivative securities in the company, indicating lack of immediate skin-in-the-game

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 06/27/2025 - 04:09 PM Learn about SEC filing dates

FAQ

Who is the new CEO and Chairman of VOR Biopharma (VOR)?

Jean-Paul Kress was appointed as the CEO and Chairman of VOR Biopharma, as disclosed in a Form 3 filing dated June 28, 2025. The filing indicates his role as both Director and CEO/Chairman of the company.

When did Jean-Paul Kress join VOR Biopharma as CEO?

According to the Form 3 filing, the date of event requiring the statement was June 25, 2025, which indicates when Jean-Paul Kress assumed his positions as CEO and Chairman at VOR Biopharma.

How many shares of VOR Biopharma does CEO Jean-Paul Kress own?

According to the Form 3 filing, Jean-Paul Kress owns no securities beneficially as of the filing date (June 28, 2025). The filing explicitly states 'No securities are beneficially owned' in the Explanation of Responses section.

Does VOR's new CEO Jean-Paul Kress hold any stock options or derivative securities?

No, the Form 3 filing shows that Jean-Paul Kress does not hold any derivative securities (such as stock options, warrants, or convertible securities) in VOR Biopharma as of the filing date.

What positions does Jean-Paul Kress hold at VOR Biopharma (VOR)?

According to the Form 3 filing, Jean-Paul Kress holds multiple positions at VOR Biopharma: he serves as both a Director on the board and as CEO and Chairman of the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kress Jean-Paul

(Last) (First) (Middle)

C/O VOR BIOPHARMA INC.

100 CAMBRIDGEPARK DRIVE, SUITE 101

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/25/2025

3. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Sherell Bacchas, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.